Citi analyst David Lebowitz lowered the firm’s price target on Intellia Therapeutics to $40 from $44 and keeps a Neutral rating on the shares. Post the Q2 report, Intellia remains in a strong cash position with $1.1B on its books, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NTLA:
- Cathie Wood’s ARK Investment bought 95.2K shares of Intellia Therapeutics today
- Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics reports Q2 EPS ($1.40), consensus ($1.32)
- Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates
- Intellia has positive read through from BridgeBio data, says BofA